228 related articles for article (PubMed ID: 36947362)
1. The dual and multifaceted role of relaxin-2 in cancer.
Kwantwi LB
Clin Transl Oncol; 2023 Oct; 25(10):2763-2771. PubMed ID: 36947362
[TBL] [Abstract][Full Text] [Related]
2. Targeting the relaxin hormonal pathway in prostate cancer.
Neschadim A; Summerlee AJ; Silvertown JD
Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
[TBL] [Abstract][Full Text] [Related]
3. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Thompson VC; Hurtado-Coll A; Turbin D; Fazli L; Lehman ML; Gleave ME; Nelson CC
Prostate; 2010 Jul; 70(10):1134-45. PubMed ID: 20503398
[TBL] [Abstract][Full Text] [Related]
4. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by upregulation of S100A4/MMPs signaling.
Cao WH; Liu HM; Liu X; Li JG; Liang J; Liu M; Niu ZH
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):609-17. PubMed ID: 23543443
[TBL] [Abstract][Full Text] [Related]
5. Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy.
Zhou X; Liu Y; Hu M; Wang M; Liu X; Huang L
Sci Adv; 2021 Feb; 7(8):. PubMed ID: 33597232
[TBL] [Abstract][Full Text] [Related]
6. The role of relaxin in endometrial cancer.
Kamat AA; Feng S; Agoulnik IU; Kheradmand F; Bogatcheva NV; Coffey D; Sood AK; Agoulnik AI
Cancer Biol Ther; 2006 Jan; 5(1):71-7. PubMed ID: 16322684
[TBL] [Abstract][Full Text] [Related]
7. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
Sassoli C; Nistri S; Chellini F; Bani D
Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
[TBL] [Abstract][Full Text] [Related]
8. Exosome-mediated crosstalk between tumor cells and innate immune cells: implications for cancer progression and therapeutic strategies.
Kwantwi LB
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9487-9503. PubMed ID: 37154928
[TBL] [Abstract][Full Text] [Related]
9. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
[TBL] [Abstract][Full Text] [Related]
10. Role of relaxin in human osteoclastogenesis.
Facciolli A; Ferlin A; Gianesello L; Pepe A; Foresta C
Ann N Y Acad Sci; 2009 Apr; 1160():221-5. PubMed ID: 19416193
[TBL] [Abstract][Full Text] [Related]
11. Relaxin promotes in vitro tumour growth, invasion and angiogenesis of human Saos-2 osteosarcoma cells by AKT/VEGF pathway.
Ma JF; Von Kalle M; Plautz Q; -M Xu F; Singh L; Wang L
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1345-50. PubMed ID: 23740448
[TBL] [Abstract][Full Text] [Related]
12. Human relaxin-2: historical perspectives and role in cancer biology.
Nair VB; Samuel CS; Separovic F; Hossain MA; Wade JD
Amino Acids; 2012 Sep; 43(3):1131-40. PubMed ID: 22855207
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Sasser JM
Am J Physiol Regul Integr Comp Physiol; 2013 Sep; 305(6):R559-65. PubMed ID: 23883673
[TBL] [Abstract][Full Text] [Related]
14. Relaxin promotes prostate cancer progression.
Feng S; Agoulnik IU; Bogatcheva NV; Kamat AA; Kwabi-Addo B; Li R; Ayala G; Ittmann MM; Agoulnik AI
Clin Cancer Res; 2007 Mar; 13(6):1695-702. PubMed ID: 17363522
[TBL] [Abstract][Full Text] [Related]
15. The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting.
Bathgate RAD; Kocan M; Scott DJ; Hossain MA; Good SV; Yegorov S; Bogerd J; Gooley PR
Pharmacol Ther; 2018 Jul; 187():114-132. PubMed ID: 29458108
[TBL] [Abstract][Full Text] [Related]
16. Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain.
Binder C; Chuang E; Habla C; Bleckmann A; Schulz M; Bathgate R; Einspanier A
Clin Exp Metastasis; 2014 Jan; 31(1):57-65. PubMed ID: 23963762
[TBL] [Abstract][Full Text] [Related]
17. Relaxin as a potential diagnostic biomarker for ovarian cancer- A prospective study.
Gkrozou F; Pappa C; Tsonis O; Dimitriou E; Paschopoulos M
Eur J Obstet Gynecol Reprod Biol; 2021 May; 260():99-104. PubMed ID: 33752121
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.
Burston HE; Kent OA; Communal L; Udaskin ML; Sun RX; Brown KR; Jung E; Francis KE; La Rose J; Lowitz J; Drapkin R; Mes-Masson AM; Rottapel R
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561012
[TBL] [Abstract][Full Text] [Related]
19. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics.
Dschietzig T; Bartsch C; Baumann G; Stangl K
Pharmacol Ther; 2006 Oct; 112(1):38-56. PubMed ID: 16647137
[TBL] [Abstract][Full Text] [Related]
20. Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1.
Parsell DA; Mak JY; Amento EP; Unemori EN
J Biol Chem; 1996 Nov; 271(44):27936-41. PubMed ID: 8910395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
